Safety and effect of topical neostigmine ophthalmic solution in animal models
Abstract The study aimed to evaluate the safety and effect of various dosages of topical neostigmine ophthalmic solution (TNOS) in animal models and establish a recommended dosage for further studies on myasthenia gravis (MG) diagnosis. A placebo-controlled, sequential ascending dose study was condu...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-16328-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226373448597504 |
|---|---|
| author | Chuthamas Ongprakobkul Supharat Jariyakosol Supanut Apinyawasisuk Kasem Rattanapinyopituk Pajaree Chariyavilaskul Kornvalee Meesilpavikkai Yuda Chongpison |
| author_facet | Chuthamas Ongprakobkul Supharat Jariyakosol Supanut Apinyawasisuk Kasem Rattanapinyopituk Pajaree Chariyavilaskul Kornvalee Meesilpavikkai Yuda Chongpison |
| author_sort | Chuthamas Ongprakobkul |
| collection | DOAJ |
| description | Abstract The study aimed to evaluate the safety and effect of various dosages of topical neostigmine ophthalmic solution (TNOS) in animal models and establish a recommended dosage for further studies on myasthenia gravis (MG) diagnosis. A placebo-controlled, sequential ascending dose study was conducted in healthy rabbits. Eighteen eyes were randomized to receive one of three concentrations (1.0, 1.5, and 2.5 mg/mL) of TNOS. Pupillary sizes over time were compared with control group that received normal saline solution (NSS). Mean pupillary size of the 1.5 mg/mL group was significantly smaller than control at 30 to 180 min after instillation (maximal mean difference (TNOS - NSS); mMD − 2.58, 95% confidence interval (95% CI) -4.24 to -0.93, p = 0.006). The mean pupillary size of the 2.5 mg/mL group was significantly smaller than the control at 60 to 90 min (mMD − 3.13, 95% CI -5.07 to -1.18, p = 0.005). No significant difference in pupillary size between 1.5 and 2.5 mg/mL groups was observed at any time points. No systemic or ocular complications were observed in any concentration. The 1.5 mg/mL TNOS was the lowest efficacious dose in this study without adverse effects and was considered a promising starting dose for further MG studies. |
| format | Article |
| id | doaj-art-b0209a1f3d0d4007b4e2ef1cde4a0caf |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-b0209a1f3d0d4007b4e2ef1cde4a0caf2025-08-24T11:25:45ZengNature PortfolioScientific Reports2045-23222025-08-0115111110.1038/s41598-025-16328-3Safety and effect of topical neostigmine ophthalmic solution in animal modelsChuthamas Ongprakobkul0Supharat Jariyakosol1Supanut Apinyawasisuk2Kasem Rattanapinyopituk3Pajaree Chariyavilaskul4Kornvalee Meesilpavikkai5Yuda Chongpison6Department of Ophthalmology, Faculty of Medicine, Chulalongkorn UniversityDepartment of Ophthalmology, Faculty of Medicine, Chulalongkorn UniversityDepartment of Ophthalmology, Faculty of Medicine, Chulalongkorn UniversityDepartment of Pathology, Faculty of Veterinary Science, Chulalongkorn UniversityCenter of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Department of Pharmacology, Faculty of Medicine, Chulalongkorn UniversityDepartment of Microbiology, Faculty of Medicine, Chulalongkorn UniversityBiostatistics Excellence Center, Research Affairs and Center of Excellence for Skin and Allergy Research, Faculty of Medicine, Chulalongkorn UniversityAbstract The study aimed to evaluate the safety and effect of various dosages of topical neostigmine ophthalmic solution (TNOS) in animal models and establish a recommended dosage for further studies on myasthenia gravis (MG) diagnosis. A placebo-controlled, sequential ascending dose study was conducted in healthy rabbits. Eighteen eyes were randomized to receive one of three concentrations (1.0, 1.5, and 2.5 mg/mL) of TNOS. Pupillary sizes over time were compared with control group that received normal saline solution (NSS). Mean pupillary size of the 1.5 mg/mL group was significantly smaller than control at 30 to 180 min after instillation (maximal mean difference (TNOS - NSS); mMD − 2.58, 95% confidence interval (95% CI) -4.24 to -0.93, p = 0.006). The mean pupillary size of the 2.5 mg/mL group was significantly smaller than the control at 60 to 90 min (mMD − 3.13, 95% CI -5.07 to -1.18, p = 0.005). No significant difference in pupillary size between 1.5 and 2.5 mg/mL groups was observed at any time points. No systemic or ocular complications were observed in any concentration. The 1.5 mg/mL TNOS was the lowest efficacious dose in this study without adverse effects and was considered a promising starting dose for further MG studies.https://doi.org/10.1038/s41598-025-16328-3NeostigmineMyasthenia gravisEyedropPupilAnimal models |
| spellingShingle | Chuthamas Ongprakobkul Supharat Jariyakosol Supanut Apinyawasisuk Kasem Rattanapinyopituk Pajaree Chariyavilaskul Kornvalee Meesilpavikkai Yuda Chongpison Safety and effect of topical neostigmine ophthalmic solution in animal models Scientific Reports Neostigmine Myasthenia gravis Eyedrop Pupil Animal models |
| title | Safety and effect of topical neostigmine ophthalmic solution in animal models |
| title_full | Safety and effect of topical neostigmine ophthalmic solution in animal models |
| title_fullStr | Safety and effect of topical neostigmine ophthalmic solution in animal models |
| title_full_unstemmed | Safety and effect of topical neostigmine ophthalmic solution in animal models |
| title_short | Safety and effect of topical neostigmine ophthalmic solution in animal models |
| title_sort | safety and effect of topical neostigmine ophthalmic solution in animal models |
| topic | Neostigmine Myasthenia gravis Eyedrop Pupil Animal models |
| url | https://doi.org/10.1038/s41598-025-16328-3 |
| work_keys_str_mv | AT chuthamasongprakobkul safetyandeffectoftopicalneostigmineophthalmicsolutioninanimalmodels AT supharatjariyakosol safetyandeffectoftopicalneostigmineophthalmicsolutioninanimalmodels AT supanutapinyawasisuk safetyandeffectoftopicalneostigmineophthalmicsolutioninanimalmodels AT kasemrattanapinyopituk safetyandeffectoftopicalneostigmineophthalmicsolutioninanimalmodels AT pajareechariyavilaskul safetyandeffectoftopicalneostigmineophthalmicsolutioninanimalmodels AT kornvaleemeesilpavikkai safetyandeffectoftopicalneostigmineophthalmicsolutioninanimalmodels AT yudachongpison safetyandeffectoftopicalneostigmineophthalmicsolutioninanimalmodels |